Arcus Biosciences annual operating income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences Operating Income Growth & History (RCUS)
Arcus Biosciences's operating income was −$386.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$386.0M | −$56.0M | — |
| 2024 | 2024-12-31 | −$330.0M | $10.0M | — |
| 2023 | 2023-12-31 | −$340.0M | −$60.0M | — |
| 2022 | 2022-12-31 | −$280.0M | −$334.0M | — |
| 2021 | 2021-12-31 | $54.0M | $178.0M | — |
| 2020 | 2020-12-31 | −$124.0M | −$35.3M | — |
| 2019 | 2019-12-31 | −$88.7M | −$33.9M | — |
| 2018 | 2018-12-31 | −$54.9M | −$1.4M | — |
| 2017 | 2017-12-31 | −$53.4M | −$35.3M | — |
| 2016 | 2016-12-31 | −$18.2M | — | — |
Arcus Biosciences quarterly operating income
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$96.0M | −$88.0M | — |
| Q1 2026 | 2026-03-31 | −$134.0M | −$12.0M | — |
| Q4 2025 | 2025-12-31 | −$114.0M | −$11.0M | — |
| Q3 2025 | 2025-09-30 | −$142.0M | −$37.0M | — |
| Q2 2025 | 2025-06-30 | −$8.0M | $98.0M | — |
| Q1 2025 | 2025-03-31 | −$122.0M | −$106.0M | — |
| Q4 2024 | 2024-12-31 | −$103.0M | — | — |
| Q3 2024 | 2024-09-30 | −$105.0M | −$25.0M | — |
| Q2 2024 | 2024-06-30 | −$106.0M | −$23.0M | — |
| Q1 2024 | 2024-03-31 | −$16.0M | $70.0M | — |
| Q3 2023 | 2023-09-30 | −$80.0M | −$10.0M | — |
| Q2 2023 | 2023-06-30 | −$83.0M | −$14.0M | — |
| Q1 2023 | 2023-03-31 | −$86.0M | −$19.0M | — |
| Q3 2022 | 2022-09-30 | −$70.0M | $8.1M | — |
| Q2 2022 | 2022-06-30 | −$69.0M | $7.1M | — |
| Q1 2022 | 2022-03-31 | −$67.0M | $5.7M | — |
| Q4 2021 | 2021-12-31 | $281.0M | — | — |
| Q3 2021 | 2021-09-30 | −$78.1M | −$79.7M | — |
| Q2 2021 | 2021-06-30 | −$76.1M | −$30.8M | — |
| Q1 2021 | 2021-03-31 | −$72.7M | −$44.3M | — |
| Q3 2020 | 2020-09-30 | $1.6M | $24.8M | — |
| Q2 2020 | 2020-06-30 | −$45.4M | −$16.2M | — |
| Q1 2020 | 2020-03-31 | −$28.4M | −$9.6M | — |
| Q4 2019 | 2019-12-31 | −$17.5M | −$4.0M | — |
| Q3 2019 | 2019-09-30 | −$23.2M | −$11.1M | — |
| Q2 2019 | 2019-06-30 | −$29.2M | −$13.3M | — |
| Q1 2019 | 2019-03-31 | −$18.8M | −$5.4M | — |
| Q4 2018 | 2018-12-31 | −$13.5M | −$141,000 | — |
| Q3 2018 | 2018-09-30 | −$12.1M | $11.0M | — |
| Q2 2018 | 2018-06-30 | −$15.9M | −$6.2M | — |
| Q1 2018 | 2018-03-31 | −$13.3M | −$6.0M | — |
| Q4 2017 | 2017-12-31 | −$13.3M | — | — |
| Q3 2017 | 2017-09-30 | −$23.1M | — | — |
| Q2 2017 | 2017-06-30 | −$9.7M | — | — |
| Q1 2017 | 2017-03-31 | −$7.3M | — | — |
Arcus Biosciences operating income trends
Over the last five fiscal years, Arcus Biosciences's operating income decreased from −$124.0M to −$386.0M, a change of −$262.0M. The latest reported quarter, Q2 2026, shows −$96.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
